Dexbio Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 23-10-2024
- Paid Up Capital ₹ 1.00 M
as on 23-10-2024
- Company Age 18 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 8.59 Cr
as on 23-10-2024
- Satisfied Charges ₹ 3.03 Cr
as on 23-10-2024
- Revenue -7.01%
(FY 2023)
- Profit -12.05%
(FY 2023)
- Ebitda -29.46%
(FY 2023)
- Net Worth 9.92%
(FY 2023)
- Total Assets -5.30%
(FY 2023)
About Dexbio Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹8.59 Cr. The company has closed loans amounting to ₹3.03 Cr, as per Ministry of Corporate Affairs (MCA) records.
Rajeev Chhabra, Venkata Kothuri, Venkata Subbarao, and One other member serve as directors at the Company.
- CIN/LLPIN
U24232UR2006PTC011840
- Company No.
001959
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
31 May 2006
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Uttarakhand
Industry
Company Details
- Location
Haridwar, Uttarakhand, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Dexbio Pharma?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajeev Chhabra  | Director | 23-Apr-2018 | Current |
| Venkata Kothuri | Director | 23-Aug-2006 | Current |
| Venkata Subbarao | Director | 23-Aug-2006 | Current |
| Anshul Chhabra | Director | 23-Apr-2018 | Current |
Financial Performance of Dexbio Pharma.
Dexbio Pharma Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 7.01% decrease. The company also saw a substantial fall in profitability, with a 12.05% decrease in profit. The company's net worth moved up by a moderate rise of 9.92%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Dexbio Pharma?
In 2023, Dexbio Pharma had a public holding of 31.50%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Dexbio Life Sciences Private LimitedActive 8 years 7 days
Venkata Kothuri and Venkata Subbarao are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 17 Nov 2022 | ₹2.56 Cr | Open |
Hdfc Bank Limited Creation Date: 04 Apr 2021 | ₹6.03 Cr | Open |
Canara Bank Creation Date: 06 Jan 2022 | ₹1.49 Cr | Satisfied |
How Many Employees Work at Dexbio Pharma?
Dexbio Pharma has a workforce of 30 employees as of Sep 02, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Dexbio Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Dexbio Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
